Dyne Therapeutics Inc [DYN] stock prices are down -0.10% to $31.22 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The DYN shares have gain 12.79% over the last week, with a monthly amount glided 31.76%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on May 21, 2024, when Chardan Capital Markets reiterated its Buy rating and also boosted its price target to $42 from $31. Previously, Morgan Stanley started tracking the stock with Overweight rating on April 30, 2024, and set its price target to $40. On February 20, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $36 on the stock. Raymond James upgraded its rating to a Strong Buy and increased its price target to $27 on February 27, 2023. Oppenheimer initiated its recommendation with a Outperform and recommended $34 as its price target on February 15, 2023. Guggenheim started tracking with a Buy rating for this stock on January 26, 2023, and assigned it a price target of $33. In a note dated July 20, 2022, Chardan Capital Markets initiated an Buy rating and provided a target price of $17 on this stock.
The stock price of Dyne Therapeutics Inc [DYN] has been fluctuating between $6.40 and $35.98 over the past year. Currently, Wall Street analysts expect the stock to reach $35.33 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $31.22 at the most recent close of the market. An investor can expect a potential return of 13.16% based on the average DYN price forecast.
Analyzing the DYN fundamentals
Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -70.18%, Pretax Profit Margin comes in at -67.95%, and Net Profit Margin reading is -67.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -1.11 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.72 points at the first support level, and at 30.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.88, and for the 2nd resistance point, it is at 32.53.
Ratios To Look Out For
It’s worth pointing out that Dyne Therapeutics Inc [NASDAQ:DYN]’s Current Ratio is 21.83. On the other hand, the Quick Ratio is 21.83, and the Cash Ratio is 12.16.
Transactions by insiders
Recent insider trading involved Beskrovnaya Oxana, Chief Scientific Officer, that happened on May 20 ’24 when 30426.0 shares were sold. Chief Business Officer, McNeill Jonathan completed a deal on May 16 ’24 to sell 2774.0 shares. Meanwhile, Chief Operating Officer HIGH SUSANNA GATTI sold 2738.0 shares on May 16 ’24.
